References
- Abou El-Einen, M., T. Cathomen, Z. Ivics, C. H. June, M. Renner, C. K. Schneider, and G. Bauer. 2017. “Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment.” Cell Stem Cell 21: 427–430. doi:https://doi.org/10.1016/j.tibtech.2018.06.005.
- Adashi, E. Y., and I. G. Cohen. 2015. “Editing the Genome of the Human Germline: May Cool Heads Prevail.” The American Journal of Bioethics 15 (12): 40–42. doi:https://doi.org/10.1080/15265161.2015.1103805.
- Adashi, E. Y., and I. G. Cohen. 2017. “Ideology vs. Beneficence.” Journal of Law and the Biosciences 4 (2): 365–370. doi:https://doi.org/10.1093/jlb/lsx023.
- Allyse, M., M. Michie, J. Mozersky, and R. Rapp. 2015. “Cherchez la femme: Reproductive CRISPR and Women's Choices.” The American Journal of Bioethics 15 (12): 47–49. doi:https://doi.org/10.1080/15265161.2015.1103808.
- Arnstein, S. R. 1969. “A Ladder of Citizen Participation.” Journal of the American Institute of Planners 35 (4): 216–224. doi:https://doi.org/10.1080/01944366908977225.
- Baltimore, D. 2016. “Why We Need a Summit on Human Gene Editing.” Issues in Science and Technology 32 (3): 35–38.
- Baltimore, D., P. Berg, M. Botchan, D. Carroll, R. A. Charo, G. Church, J. E. Corn, et al. 2015. “A Prudent Path Forward for Genomic Engineering and Germline Gene Modification.” Science 348 (6230): 36–38. doi:https://doi.org/10.1126/science.aab1028.
- Baltzegar, J., J. C. Barnes, J. E. Elsensohn, N. Gutzmann, M. S. Jones, S. King, and J. Sudweeks. 2018. “Anticipating Complexity in the Deployment of Gene Drive Insects in Agriculture.” Journal of Responsible Innovation 5 (sup1): S81–S97. doi:https://doi.org/10.1080/23299460.2017.1407910.
- Barben, D., E. Fisher, C. Selin, and D. H. Guston. 2008. “Anticipatory Governance of Nanotechnology: Foresight, Engagement, and Integration.” In The Handbook of Science and Technology Studies, edited by E. J. Hackett, O. Amsterdamska, M. Lynch, and J. Wajcman, 3rd ed., 979–1000. Cambridge, MA: The MIT Press.
- Baylis, F., and M. McLeod. 2017. “First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?” Current Gene Therapy 17 (4): 309–319. doi:https://doi.org/10.2174/1566523217666171121165935.
- Beckman, E. S., N. Deuitch, M. Michie, M. A. Allyse, K. A. Riggan, and K. E. Ormond. 2019. “Attitudes Toward Hypothetical Uses of Gene-Editing Technologies in Parents of People with Autosomal Aneuploidies.” The CRISPR Journal 2 (5): 324–330. doi:https://doi.org/10.1089/crispr.2019.0021.
- Bertrand, P., Z. Pirtle, and D. Tomblin. 2017. “Participatory Technology Assessment for Mars Mission Planning: Public Values and Rationales.” Space Policy 42: 41–53. doi:https://doi.org/10.1016/j.spacepol.2017.08.004.
- Bibikova, M., M. Golic, K. G. Golic, and D. Carroll. 2002. “Targeted Chromosomal Cleavage and Mutagenesis in Drosophila Using Zinc-Finger Nucleases.” Genetics 161 (3): 1169–1175.
- Bishop, P., A. Hines, and T. Collins. 2007. “The Current State of Scenario Development: an Overview of Techniques.” Foresight 9 (1): 5–25. doi:https://doi.org/10.1108/14636680710727516.
- Blaese, R. M., K. W. Culver, A. D. Miller, C. S. Carter, T. Fleisher, M. Clerici, et al. 1995. “T Lymphocyte-Directed Gene Therapy for ADA-SCID: Initial Trial Results After 4 Years.” Science 270 (5235): 475–480. doi:https://doi.org/10.1126/science.270.5235.475.
- Blendon, R. J., M. T. Gorski, and J. M. Benson. 2016. “The Public and the Gene-Editing Revolution.” The New England Journal of Medicine 374 (15): 1406–1411. doi:https://doi.org/10.1056/NEJMp1602010.
- Boaz, A., D. Biri, and C. McKevitt. 2016. “Rethinking the Relationship Between Science and Society: Has There Been a Shift in Attitudes to Patient and Public Involvement and Public Engagement in Science in the United Kingdom?” Health Expectations 19 (3): 592–601. doi:https://doi.org/10.1111/hex.12295.
- Bonvillian, W. B., and R. Van Atta. 2011. “ARPA-E and DARPA: Applying the DARPA Model to Energy Innovation.” The Journal of Technology Transfer 36: 469–513. doi:https://doi.org/10.1007/s10961-011-9223-x.
- Borgelt, E. L., S. Dharamsi, and C. T. Scott. 2013. “Dear Student: Stem Cell Scientists’ Advice to the Next Generation.” Cell Stem Cell 12 (6): 652–655. doi:https://doi.org/10.1016/j.stem.2013.05.007.
- Bovenkerk, B. 2015. “Scientific Responsibility: Should Analysis Start with the Scientists?” The American Journal of Bioethics 15 (12): 66–68. doi:https://doi.org/10.1080/15265161.2015.1103807.
- Bozeman, B. 2007. Public Values and Public Interest: Counterbalancing Economic Individualism. Washington, DC: Georgetown University Press.
- Bozeman, B., and D. Sarewitz. 2011. “Public Value Mapping and Science Policy Evaluation.” Minerva 49: 1–23. doi:https://doi.org/10.1007/s11024-011-9161-7.
- Brokowski, C. 2018. “Do CRISPR Germline Ethics Statements Cut It?” The CRISPR Journal 1 (2): 115–125. doi:https://doi.org/10.1089/crispr.2017.0024.
- Brown, N. 2003. “Hope Against Hype—Accountability in Biopasts, Presents and Futures.” Science Studies 16 (2): 3–21.
- Burall, S. 2018. “Rethink Public Engagement for Gene Editing.” Nature 555: 438–439. doi: https://doi.org/10.1038/d41586-018-03269-3.
- Burns, E. T., J. A. Flegal, D. W. Keith, A. Mhajan, D. Tingley, and G. Wagner. 2016. “What Do People Think When They Think About Solar Geoengineering? A Review of Empirical Social Science Literature, and Prospects for Future Research.” Earth’s Future 4 (11): 536–542. doi:https://doi.org/10.1002/2016EF000461.
- Bush, V. 1945. Science the Endless Frontier, A Report to the President. Washington, DC: United States Government Printing Office.
- Callahan, D. 2015. “Gene Editing: Hope, Hype, and Caution.” Hastings Center Post, December, 8. https://web.archive.org/web/20190413112322/https://www.thehastingscenter.org/gene-editing-hope-hype-and-caution/.
- Cavalier, D., and E. B. Kennedy. 2016. The Rightful Place of Science: Citizen Science. Tempe, AZ: Consortium for Science, Policy & Outcomes.
- Chan, S., P. J. Donovan, T. Douglas, C. Gyngell, J. Harris, R. Lovell-Badge, D. J. H. Mathews, and A. Regenberg. 2015. “Genome Editing Technologies and Human Germline Genetic Modification: The Hinxton Group Consensus Statement.” The American Journal of Bioethics 15 (12): 42–47. doi:https://doi.org/10.1080/15265161.2015.1103814.
- Chhetri, N., R. Ghimire, M. Wagner, and M. Wang. 2020. “Global Citizen Deliberation: Case of World-Wide Views on Climate and Energy.” Energy Policy 147: 111892. doi:https://doi.org/10.1016/j.enpol.2020.111892.
- Chneiweiss, H., F. Hirsch, L. Montoliu, A. M. Müeller, S. Fenet, M. Abecassis, et al. 2017. “Fostering Responsible Research with Genome Editing Technologies: a European Perspective.” Transgenic Research 26: 709–713. doi:https://doi.org/10.1007/s11248-017-0028-z.
- Church, G. 2015. “Perspective: Encourage the Innovators.” Nature 528: S7. doi:https://doi.org/10.1038/528S7a.
- Church, G. 2017. “Compelling Reasons for Repairing Human Germlines.” The New England Journal of Medicine 377 (20): 1909–1911. doi:https://doi.org/10.1056/NEJMp1710370.
- Cohen, J. 2020. “The Latest Round in the CRISPR Patent Battle has an Apparent Victor, But the Fight Continues.” Science September 11. doi:https://doi.org/10.1126/science.abe7573.
- Collingridge, D. 1980. The Social Control of Technology. Milton Keynes: Open University Press.
- Conley, S. N. 2020. “Who Gets to be Born? The Anticipatory Governance of Pre-Implantation Genetic Diagnosis Technology in the United Kingdom from 1978-2001.” Journal of Responsible Innovation 7 (3): 507–527. doi:https://doi.org/10.1080/23299460.2020.1802544.
- Contreras, J., and J. S. Sherkow. 2017. “CRISPR, Surrogate Licensing, and Scientific Discovery.” Science 355 (6326): 698–700. doi: https://doi.org/10.1126/science.aal4222.
- Couzin, J., and J. Kaiser. 2005. “Gene Therapy: As Gelsinger Case Ends, Gene Therapy Suffers Another Blow.” Science 307 (5712): 1028b. doi:https://doi.org/10.1126/science.307.5712.1028b.
- Doubleday, R., and B. Wynne. 2011. “Despotism and Democracy in the UK: Experiments in Reframing Citizenship.” In Reframing Rights: Bioconstitutionalism in the Genetic Age, edited by S. Jasanoff, 239–262. Cambridge, MA: MIT Press.
- Doudna, J. 2015. “Perspective: Embryo Editing Needs Scrutiny.” Nature 528: S6. doi:https://doi.org/10.1038/528S6a.
- Doudna, J. A., and E. Charpentier. 2014. “The new Frontier of Genome Engineering with CRISPR-Cas9.” Science 346 (6213): 1258019-1–1258096-9. doi:https://doi.org/10.1126/science.1258096.
- Douglas, M., and A. Wildavsky. 1982. Risk and Culture: An Essay on the Selection of Technological and Environmental Dangers. Berkeley, CA: University of California Press.
- Dryzek, J. S., D. Nicol, S. Niemeyer, S. Pemberton, N. Curato, A. Bächtiger, P. Batterham, et al. 2020. “Global Citizen Deliberation on Genome Editing.” Science 369 (6510): 1435–1437.
- Dryzek, J. S., and A. S. Tucker. 2008. “Deliberative Innovation to Different Effect. Consensus Conferences in Denmark, France, and the United States.” Public Administration Review 68 (5): 864–876. doi:https://doi.org/10.1111/j.1540-6210.2008.00928.x.
- Durant, J. 1999. “Participatory Technology Assessment and the Democratic Model of the Public Understanding of Science.” Science and Public Policy 26 (5): 313–319. doi:https://doi.org/10.3152/147154399781782329.
- European Commission. (2013) 2015. Horizon 2020 Work Programme 2014-2015: 16. Science with and for Society (Revised). http://ec.europa.eu/research/participants/data/ref/h2020/wp/2014_2015/main/h2020-wp1415-swfs_en.pdf#14.
- Evans, J. H. 2002. Playing God?: Human Genetic Engineering and the Rationalization of Public Bioethical Debate. Chicago, IL: University of Chicago Press.
- Felt, U., and B. Wynne. 2007. Taking European Knowledge Society Seriously: Report of the Expert Group on Science and Governance to the Science, Economy and Society Directorate, Directorate-General for Research, European Commission. Luxembourg, BY: Office for Official Publications of the European Communities.
- Fisher, E. 2019. “Governing with Ambivalence: The Tentative Origins of Socio-Technical Integration.” Research Policy 48 (5): 1138–1149. doi:https://doi.org/10.1016/j.respol.2019.01.010.
- Fisher, E., and G. Maricle. 2015. “Higher-level Responsiveness? Socio-Technical Integration Within US and UK Nanotechnology Research Priority Setting.” Science and Public Policy 42: 72–85. doi:https://doi.org/10.1093/scipol/scu017.
- Fisher, E., R. L. Mahajan, and C. Mitcham. 2006. “Midstream Modulation of Technology: Governance from Within. Bulletin of Science.” Technology & Society 26 (6): 485–496. doi:https://doi.org/10.1177/0270467606295402.
- Fisher, E., M. O’Rourke, R. Evans, E. B. Kennedy, M. E. Gorman, and T. P. Seager. 2015. “Mapping the Integrative Field: Taking Stock of Socio-Technical Collaborations.” Journal of Responsible Innovation 2 (1): 39–61. doi:https://doi.org/10.1080/23299460.2014.1001671.
- Funk, C., and M. Hefferon. 2019. “Public Views of Gene Editing for Babies Depend on How it Would be Used.” Pew Research Center Science & Society, July 26. https://www.pewresearch.org/science/2018/07/26/public-views-of-gene-editing-for-babies-depend-on-how-it-would-be-used/.
- Funtowicz, S., and J. Ravetz. 1993. “Science for the Post-Normal Age.” Futures 25: 739–755. doi:https://doi.org/10.1016/0016-3287(93)90022-L.
- Gaskell, G., I. Bard, A. Allansdottir, R. V. da Cunha, P. Eduard, J. Hampel, E. Hildt, et al. 2017. “Public Views on Gene Editing and its Uses.” Nature Biotechnology 35 (11): 1021–1023. doi:https://doi.org/10.1038/nbt.3958.
- Genus, A., and A. Stirling. 2018. “Collingridge and the Dilemma of Control: Towards Responsible and Accountable Innovation.” Research Policy 47 (1): 61–69. doi:https://doi.org/10.1016/j.respol.2017.09.012.
- German Ethics Council. 2019. Intervening in the Human Germline: Opinion-Executive Summary & Recommendations. Translated by A. Sharpe. Berlin: German Ethics Council.
- Gewin, V. 2017. “Communication: Post-Truth Predicaments.” Nature 541: 425–427. doi:https://doi.org/10.1038/nj7637-425a.
- Greely, H. T. 2019a. “CRISPR'd Babies: Human Germline Genome Editing in the 'He Jiankui Affair.” Journal of Law and the Biosciences 6 (1): 111–183. doi:https://doi.org/10.1093/jlb/lsz010.
- Greely, H. T. 2019b. “Human Germline Genome Editing: An Assessment.” The CRISPR Journal 2 (5): 253–265. doi:https://doi.org/10.1089/crispr.2019.0038.
- Guerrini, C. J., M. A. Curnutte, J. S. Sherkow, and C. T. Scott. 2017. “The Rise of the Ethical License.” Nature Biotechnology 35 (1): 22–24. doi:https://doi.org/10.1038/nbt.3756.
- Guston, D. H. 2010. “The Anticipatory Governance of Emerging Technologies.” Journal of the Korean Vacuum Society 19 (6): 432–441. doi: https://doi.org/10.5757/JKVS.2010.19.6.432
- Guston, D. H. 2011. “Participating Despite Questions: Toward a More Confident Participatory Technology Assessment.” Science and Engineering Ethics 17: 691–697. doi:https://doi.org/10.1007/s11948-011-9314-y.
- Guston, D. H. 2014. “Understanding ‘Anticipatory Governance’.” Social Studies of Science 44 (2): 218–242. doi:https://doi.org/10.1177/0306312713508669.
- Guston, D., and D. Sarewitz. 2002. “Real-time Technology Assessment.” Technology in Society 24 (1-2): 93–109. doi:https://doi.org/10.1016/S0160-791X(01)00047-1.
- Halpern, J., S. E. O'Hara, K. W. Doxzen, L. B. Witkowsy, and A. L. Owen. 2019. “Societal and Ethical Impacts of Germline Genome Editing: How Can We Secure Human Rights?” The CRISPR Journal 2 (4): 293–298. doi:https://doi.org/10.1089/crispr.2019.0042.
- Harris, J. 2015. “Germline Manipulation and Our Future Worlds.” The American Journal of Bioethics 15 (12): 30–34. doi:https://doi.org/10.1080/15265161.2015.1104163.
- Harvard School of Public Health & STAT. 2016. The Public and Genetic Editing, Testing, and Therapy. Cambridge, MA: Harvard T.H. Chan School of Public Health.
- Harvey, A., and B. Salter. 2012. “Anticipatory Governance: Bioethical Expertise for Human/Animal Chimeras.” Science as Culture 21 (3): 291–313. doi:https://doi.org/10.1080/09505431.2011.630069.
- HHS [U.S. Department of Health and Human Services]. 1979. The Belmont Report. https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report.
- Hilgartner, S. 2015. “Capturing the Imaginary: Vanguards, Visions, and the Synthetic Biology Revolution.” In Science and Democracy: Making Knowledge and Making Power in the Biosciences and Beyond, edited by S. Hilgartner, C. Miller, and R. Hagendijk, 33–55. New York, NY: Routledge.
- Hurlbut, J. B. 2015. “Limits of Responsibility: Genome Editing, Asilomar, and the Politics of Deliberation.” Hastings Center Report 45 (5): 11–14. doi:https://doi.org/10.1002/hast.484.
- Hurlbut, J. B. 2017. Experiments in Democracy: Human Embryo Research and the Politics of Bioethics. New York, NY: Columbia University Press.
- Hurlbut, J. B. 2018. “In CRISPR’s World: Genome Editing and the Politics of Global Science.” In Routledge Handbook of Genomics and Society, edited by S. Gibbon, B. Prainsack, S. Hilgartner, and J. Lamoreaux, 2nd ed., 169–178. London: Routledge. doi:https://doi.org/10.4324/9781315451695.
- Hurlbut, J. B., S. Jasanoff, K. Saha, A. Ahmed, A. Appiah, E. Bartholet, F. Baylis, et al. 2018. “Building Capacity for a Global Genome Editing Observatory: Conceptual Challenges.” Trends in Biotechnology 36 (7): 639–641. doi:https://doi.org/10.1016/j.tibtech.2018.04.009.
- Jalbert, K., S. M. Rubright, and K. Edelstein. 2017. “The Civic Informatics of FracTracker Alliance: Working with Communities to Understand the Unconventional Oil and Gas Industry.” Engaging Science, Technology, and Society 3: 528–559. doi:https://doi.org/10.17351/ests2017.128.
- Jasanoff, S. 2005. Designs on Nature. Princeton, NJ: Princeton University Press.
- Jasanoff, S. 2015. “Future Imperfect: Science, Technology, and the Imaginations of Modernity.” In Dreamscapes of Modernity, edited by Sheila Jasanoff and Sang-Huyn Kim, 1–33. Chicago, IL: Chicago University Press.
- Jasanoff, S. 2018. Can Science Make Sense of Life? Cambridge, UK: Polity Press.
- Jasanoff, S., J. B. Hurlbut, and K. Saha. 2015. “CRISPR Democracy: Gene Editing and the Need for Inclusive Deliberation.” Issues in Science and Technology 32 (1), https://issues.org/crispr-democracy-gene-editing-and-the-need-for-inclusive-deliberation/.
- Jasanoff, S., J. B. Hurlbut, and K. Saha. 2019. “Democratic Governance of Human Germline Genome Editing.” The CRISPR Journal 2 (5): 266–271. doi:https://doi.org/10.1089/crispr.2019.0047.
- Jasanoff, S., and H. R. Simmet. 2017. “No Funeral Bells: Public Reason in a ‘Post-Truth’ Age.” Social Studies of Science 47 (5): 751–770. doi:https://doi.org/10.1177/0306312717731936.
- Jasanoff, S., and J. B. Hurlbut. 2018. “A Global Observatory for Gene Editing.” Nature 555: 435–437. doi: https://doi.org/10.1038/d41586-018-03270-w.
- Jinek, M., K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna, and E. Charpentier. 2012. “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity.” Science 337 (6096): 816–821. doi:https://doi.org/10.1126/science.1225829.
- Jinek, M., A. East, A. Cheng, S. Lin, E. Ma, and J. Doudna. 2013. “RNA-programmed Genome Editing in Human Cells.” eLife 2: e00471. doi:https://doi.org/10.7554/eLife.00471.
- Joly, P. 2015. “Governing Emerging Technologies? The Need to Think Outside the (Black) Box.” In Science and Democracy: Making Knowledge and Making Power in the Biosciences and Beyond, edited by S. Hilgartner, C. Miller, and R. Hagendijk, 33–55. New York, NY: Routledge.
- Jones, D. G., M. Whitaker, and M. King. 2011. “Speculative Ethics: Valid Enterprise or Tragic cul-de-sac?” In Bioethics in the 21st Century (Online), edited by A. Rudnick. Intech. https://www.intechopen.com/books/bioethics-in-the-21st-century/speculative-ethics-valid-enterprise-or-tragic-cul-de-sac-.
- Juengst, E. T. 2017. “Crowdsourcing the Moral Limits of Human Gene Editing?” Hastings Center Report 47 (3): 15–23. doi:https://doi.org/10.1002/hast.701.
- Juengst, E. T., G. E. Henderson, R. L. Walker, J. M. Conley, D. MacKay, K. M. Meagher, K. Saylor, M. Waltz, K. J. Kuczynski, and R. J. Cadigan. 2018. “Is Enhancement the Price of Prevention in Human Gene Editing?” The CRISPR Journal 1 (6): 351–354. doi:https://doi.org/10.1089/crispr.2018.0040.
- Kang, X., W. He, Y. Huang, Q. Yu, Y. Chen, X. Gao, X. Sun, and Y. Fan. 2016. “Introducing Precise Genetic Modifications into Human 3PN Embryos by CRISPR/Cas-Mediated Genome Editing.” Journal of Assisted Reproduction and Genetics 33 (5): 581–588. doi:https://doi.org/10.1007/s10815-016-0710-8.
- Kaplan, L., J. Nelson, D. Tomblin, M. Farooque, J. Lloyd, M. Neff, B. Bedsted, and D. Sarewitz. 2019. Exploring Democratic Governance of Geoengineering Research Through Public and Stakeholder Engagement. Washington, DC: Consortium for Science, Policy & Outcomes.
- Kim, J. 2016. “Genome Editing Comes of Age.” Nature Protocols 11 (9): 1573–1578. doi:https://doi.org/10.1038/nprot.2016.104.
- King, N. M. P., P. C. Lord, and D. E. Lemley. 2017. “Editing the Genome: Prospects, Progress, Implications, and Cautions.” Current Genetic Medicine Reports 5: 35–43. doi:https://doi.org/10.1007/s40142-017-0109-6.
- Knoppers, B. M., and E. Kleiderman. 2019. “Heritable Genome Editing: Who Speaks for “Future” Children?” The CRISPR Journal 2 (5): 285–292. doi:https://doi.org/10.1089/crispr.2019.0019.
- Konrad, K., H. Van Lente, C. Groves, and C. Selin. 2016. “Performing and Governing the Future in Science and Technology.” In The Handbook of Science and Technology Studies, edited by U. Felt, R. Fouché, C. Miller, and L. Smith-Doerr, 4th ed., 465–494. Cambridge, MA: MIT Press.
- Kostick, K., L. R. Folwer, and C. T. Scott. 2019. “A Matter of Life and Longer Life.” Journal of Aging Studies 50: 100800. doi:https://doi.org/10.1016/j.jaging.2019.100800.
- Krimsky, S. 2019. “The Moral Choices on CRISPR Babies.” The American Journal of Bioethics 19 (1): 15–16. doi:https://doi.org/10.1080/15265161.2019.1644824.
- Kuzdas, C., and A. Wiek. 2014. “Governance Scenarios for Addressing Water Conflicts and Climate Change Impacts.” Environmental Science & Policy 42: 181–196. doi:https://doi.org/10.1016/j.envsci.2014.06.007.
- Kuzma, J., F. Gould, Z. Brown, J. Collins, J. Delborne, E. Frow, K. Esvelt, et al. 2018. “A Roadmap for Gene Drives: Using Institutional Analysis and Development to Frame Research Needs and Governance in a Systems Context.” Journal of Responsible Innovation 5 (sup1): S13–S39. doi:https://doi.org/10.1080/23299460.2017.1410344.
- The Lancet. 2017. “Genome Editing: Science, Ethics, and Public Engagement.” The Lancet 390: 625. doi:https://doi.org/10.1016/S0140-6736(17)32209-2.
- Lander, E. S., F. Baylis, F. Zhang, E. Charpentier, P. Berg, C. Bourgain, B. Friedrich, et al. 2019. “Adopt a Moratorium on Heritable Genome Editing.” Nature 567: 165–168. doi:https://doi.org/10.1038/d41586-019-00726-5.
- Lanphier, E., F. Urnov, S. E. Haecker, M. Werner, and J. Smolenski. 2015. “Don't Edit the Human Germ Line.” Nature 519 (7544): 410–411. doi:https://doi.org/10.1038/519410a.
- Liang, P., Y. Xu, X. Zhang, C. Ding, R. Huang, Z. Zhang, J. Lv, et al. 2015. “CRISPR/Cas9-Mediated Gene Editing in Human Tripronuclear Zygotes.” Protein & Cell 6 (5): 363–372. doi:https://doi.org/10.1007/s13238-015-0153-5.
- Ma, H., N. Marti-Gutierrez, S. Park, J. Wu, Y. Lee, K. Suzuki, A. Koski, et al. 2017. “Correction of a Pathogenic Gene Mutation in Human Embryos.” Nature 548: 413–419. doi:https://doi.org/10.1038/nature23305.
- Macintosh, K. L. 2019. “Heritable Genome Editing and the Downsides of a Global Moratorium.” The CRISPR Journal 2 (5): 272–279. doi:https://doi.org/10.1089/crispr.2019.0016.
- Mali, P., L. Yang, K. M. Esvelt, J. Aach, M. Guell, J. E. DiCarlo, J. E. Norville, and G. M. Church. 2013. “RNA-guided Human Genome Engineering via Cas9.” Science 339 (6121): 823–826. doi:https://doi.org/10.1126/science.1232033.
- Mathews, D. J. H., R. Lovell-Badge, S. Chan, P. J. Donovan, T. Douglas, C. Gyngell, J. Harris, and A. Regenberg. 2015. “A Path Through the Thicket.” Nature 527: 160–161. doi:https://doi.org/10.1038/527159a.
- Michelson, E. S. 2016. Assessing the Societal Implications of Emerging Technologies. Milton Park: Routledge.
- Michie, M., and M. Allyse. 2019. “Gene Modification Therapies: Views of Parents of People with Down Syndrome.” Genetics in Medicine 21 (2): 487–492. doi:https://doi.org/10.1038/s41436-018-0077-6.
- Miles, I., J. C. Harper, L. Georghiou, M. Keenan, and R. Popper. 2008. “The Many Faces of Foresight.” In The Handbook of Technology Foresight: Concepts and Practice, edited by L. Georghiou, J. C. Harper, M. Keenan, I. Miles, and R. Popper, 3–23. Cheltenham, UK: Edward Elgar.
- Miller, J. C., S. Tan, G. Qiao, K. A. Barlow, J. Wang, D. F. Xia, X. Meng, et al. 2011. “A TALE Nuclease Architecture for Efficient Genome Editing.” Nature Biotechnology 29: 143–148. doi:https://doi.org/10.1038/nbt.1755.
- Mintz, R. L., J. D. Loike, and R. L. Fischbach. 2019. “Will CRISPR Germline Engineering Close the Door to an Open Future?” Science and Engineering Ethics 25: 1409–1423. doi:https://doi.org/10.1007/s11948-018-0069-6.
- Montoliu, L., J. Merchant, F. Hirsch, M. Abecassis, P. Jouannet, B. Baertschi, C. Sarrauste de Menthiére, and H. Chneiweiss. 2018. “ARRIGE Arrives: Toward the Responsible Use of Genome Editing.” The CRISPR Journal 1 (2): 128–130. doi:https://doi.org/10.1089/crispr.2018.29013.mil.
- National Academy of Sciences. 2020. Heritable Human Genome Editing. Washington, DC: The National Academies Press. doi:https://doi.org/10.17226/25665.
- National Academies of Sciences, Engineering, and Medicine. 2015. “On Human Gene Editing: International Summit Statement.” December 3, https://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=12032015a.
- National Academies of Sciences, Engineering, and Medicine. 2018. “On Human Genome Editing II: Statement by the Organizing Committee of the Second International Summit on Human Genome Editing.” November 29, http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=11282018b.
- National Academies of Sciences, Engineering, and Medicine, 2017. 2017. Human Genome Editing: Science, Ethics, and Governance. Washington, DC: The National Academies Press. doi:https://doi.org/10.17226/24623.
- National Research Council. 2008. Public Participation in Environmental Assessment and Decision Making. Washington, DC: The National Academies Press.
- Neuhaus, C. P., and A. L. Caplan. 2017. “Genome Editing: Bioethics Shows the Way.” PLoS Biology 15 (3): e2001934. doi:https://doi.org/10.1371/journal.pbio.2001934.
- Nordmann, A. 2010. “A Forensics of Wishing: Technology Assessment in the Age of Technoscience.” Poiesis & Praxis 7 (1-2): 5–15. doi:https://doi.org/10.1007/s10202-010-0081-7.
- Nuffield Council on Bioethics. 2016. Genome Editing: An Ethical Review. London: Nuffield Council on Bioethics.
- Nuffield Council on Bioethics. 2018. Genome Editing and Human Reproduction: Social and Ethical Issues. London: Nuffield Council on Bioethics.
- Ogilvy, J., and P. Schwartz. 2004. Plotting Your Scenarios. Emeryville, CA: Global Business Network.
- Ormond, K. E., D. P. Mortlock, D. T. Scholes, Y. Bombard, L. C. Brody, W. A. Faucett, N. A. Garrison, et al. 2017. “ASHG Position Statement: Human Germline Genome Editing.” The American Journal of Human Genetics 101: 167–176. doi:https://doi.org/10.1016/j.ajhg.2017.06.012.
- Owen, R., P. Macnaghten, and J. Stilgoe. 2012. “Responsible Research and Innovation: From Science in Society to Science for Society, with Society.” Science and Public Policy 39 (6): 751–760. doi:https://doi.org/10.1093/scipol/scs093.
- Pei, D., D. W. Beier, E. Levy-Lahad, G. Marchang, J. Rossant, J. C. I. Belmote, R. Lovell-Badge, R. Jaenisch, A. Charo, and D. Baltimore. 2017. “Human Embryo Editing: Opportunities and Importance of Transnational Cooperation.” Cell Stem Cell 21: 423–426. doi:https://doi.org/10.1016/j.stem.2017.09.010.
- Pew Research Center. 2015. “Public Views About Biomedical Issues.” Chap. 5 in Americans, Politics and Science Issues, 105–126. Washington, DC: Pew Research Center. https://www.pewresearch.org/internet/wp-content/uploads/sites/9/2015/07/2015-07-01_science-and-politics_FINAL-1.pdf.
- Pew Research Center. 2016a. U.S. Public Wary About Use of Biomedical Technologies to ‘Enhance’ Human Abilities. Washington, DC: Pew Research Center.
- Pew Research Center. 2016b. American Voices on Ways Human Enhancement Could Shape Our Future. Washington, DC: Pew Research Center.
- Pielke, R. A., Jr. 2007. The Honest Broker: Making Sense of Science in Policy and Politics. Cambridge, UK: Cambridge University Press. doi:https://doi.org/10.1017/CBO9780511818110.
- Polanyi, M. 1962. “The Republic of Science.” Minerva 1 (1): 54–73. doi:https://doi.org/10.1007/BF01101453.
- Racine, E. R., T. Martin Rubio, J. Chandler, C. Fortini, and J. Lucke. 2014. “The Value and Pitfalls of Speculation About Science and Technology in Bioethics: The Case of Cognitive Enhancement.” Medicine, Health Care, and Philosophy 17 (3): 325–337. doi:https://doi.org/10.1007/s11019-013-9539-4.
- Rai, A. K., and R. Cook-Deegan. 2017. “Racing for Academic Glory and Patents: Lessons from CRISPR.” Science 358 (6365): 874–876. doi:https://doi.org/10.1126/science.aao2468.
- Ramírez, R., and C. Selin. 2014. “Plausibility and Probability in Scenario Planning.” Foresight 16 (1): 54–74. doi:https://doi.org/10.1108/FS-08-2012-0061.
- Ramsay, S. 2001. “No Closure in Sight for the 10/90 Health Research Gap.” The Lancet 358: 1348.
- Rask, M. 2013. “The Tragedy of Citizen Deliberation—Two Cases of Participatory Technology Assessment.” Technology Analysis & Strategic Management, 33–55. doi:https://doi.org/10.1080/09537325.2012.751012.
- Rask, M., and R. Worthington. 2015. Governing Biodiversity Through Democratic Deliberation. Abingdon, Oxon: Routledge.
- Rayner, S., and R. Cantor. 1987. “How Fair is Safe Enough? The Cultural Approach to Societal Technology Choice.” Risk Analysis 7 (1): 3–9. doi:https://doi.org/10.1111/j.1539-6924.1987.tb00963.x.
- Regalado, A. 2018. “EXCLUSIVE: Chinese Scientists are Creating CRISPR Babies.” MIT Technology Review, November 25 (online). https://www.technologyreview.com/2018/11/25/138962/exclusive-chinese-scientists-are-creating-crispr-babies/.
- Ribeiro, B., L. Bengtsson, P. Benneworth, S. Bührer, E. Castro-Martínez, M. Hansen, K. Jarmai, et al. 2018. “Introducing the Dilemma of Societal Alignment for Inclusive and Responsible Research and Innovation.” Journal of Responsible Innovation 5 (3): 316–331. doi:https://doi.org/10.1080/23299460.2018.1495033.
- Riggan, K. A., R. R. Sharp, and M. Allyse. 2019. “Where Will We Draw the Line? Public Opinions of Human Gene Editing.” Qualitative Health Research 29 (12): 1823–1835. doi:https://doi.org/10.1177/1049732319846867.
- Rodríguez, H., E. Fisher, and D. Schuurbiers. 2013. “Integrating Science and Society in European Framework Programmes: Trends in Project-Level Solicitations.” Research Policy 42 (5): 1126–1137. doi:https://doi.org/10.1016/j.respol.2013.02.006.
- Rose, K. M., K. Korzekwa, D. Brossard, D. A. Scheufele, and L. Heisler. 2017. “Engaging the Public at a Science Festival: Findings from a Panel on Human Gene Editing.” Science Communication 39 (2): 250–277. doi:https://doi.org/10.1177/1075547017697981.
- Rosenberg, N. 1994. Exploring the Black Box: Technology Economics and History. Cambridge, UK: Cambridge University Press.
- Rueda-Sabater, E., and D. Derosby. 2011. “The Evolving Internet in 2025: Four Scenarios.” Strategy & Leadership 39 (1): 32–38. doi:https://doi.org/10.1108/10878571111095402.
- Saey, T. H. 2019. “CRISPR Enters its First Human Clinical Trials.” Science News, August 14 (online). https://www.sciencenews.org/article/crispr-gene-editor-first-human-clinical-trials.
- Saha, K., J. B. Hurlbut, S. Jasanoff, A. Ahmed, A. Appiah, E. Bartholet, F. Baylis, et al. 2018. “Building Capacity for a Global Genome Editing Observatory: Institutional Design.” Trends in Biotechnology 36 (8): 741–743. doi:https://doi.org/10.1016/j.tibtech.2018.04.008.
- Sarewitz, D. R. 2015. “CRISPR: Science Can't Solve it.” Nature 522 (7557): 413–414. doi:https://doi.org/10.1038/522413a.
- Sarewitz, D. R., and R. A. Pielke, Jr. 2000. “Prediction in Science and Policy.” In Prediction: Science, Decision Making, and the Future of Nature, edited by D. Sarewitz, R. A. Pielke, Jr., and R. A. Byerly, Jr., 11–22. Covelo, CA: Island Press.
- Sarewitz, D. R., and R. A. Pielke, Jr. 2007. “The Neglected Heart of Science Policy: Reconciling Supply of and Demand for Science.” Environmental Science & Policy 10: 5–16. doi:https://doi.org/10.1016/j.envsci.2006.10.001.
- Scheufele, D. A., M. A. Xenos, E. L. Howell, K. M. Rose, D. Brossard, and B. W. Hardy. 2017. “U.S. Attitudes on Human Genome Editing.” Science 357 (6351): 553–554. doi:https://doi.org/10.1126/science.aan3708.
- Schick, A. 2017. “Bioethics and the Legitimation/Regulation of the Imagined Future.” In Imagined Futures in Science, Technology and Society, edited by G. Verschraegen, F. Vandermoere, L. Braeckmans, and B. Segaert, 15–44. New York, NY: Routledge. doi:https://doi.org/10.4324/9781315440842.
- Sclove, R. 2010. Reinventing Technology Assessment: A 21st Century Model. Washington, DC: Woodrow Wilson International Center for Scholars.
- Scott, C. T., and L. DeFrancesco. 2015. “Selling Long Life.” Nature Biotechnology 33: 31–40. doi:https://doi.org/10.1038/nbt.3108.
- Scott, C. T., and C. Selin. 2019. “What to Expect When Expecting CRISPR Baby Number Four.” The American Journal of Bioethics 19 (3): 7–9. doi:https://doi.org/10.1080/15265161.2018.1562793.
- Selin, C. 2008. “The Sociology of the Future: Tracing Stories of Technology and Time.” Sociology Compass 2(6): 1878–1895. doi:https://doi.org/10.1111/j.1751-9020.2008.00147.x.
- Selin, C. 2012. “Professional Dreamers: The Future in the Past of Scenario Planning.” In Scenarios for Success: Turning Insights into Action, edited by B. Sharpe, and K. Van der Heijden, 27–52. Hoboken, NJ: John Wiley & Sons.
- Selin, C. 2014. “On not Forgetting Futures.” Journal of Responsible Innovation 1 (1): 103–108. doi:https://doi.org/10.1080/23299460.2014.884378.
- Selin, C. 2015. “Merging Art and Design in Foresight: Making Sense of Emerge.” Futures 70: 24–35. doi:https://doi.org/10.1016/j.futures.2014.12.006.
- Selin, C., K. Campbell Rawlings, K. de Ridder-Vignone, J. Sadowski, C. Altamirano Allende, G. Gano, S. R. Davies, and D. H. Guston. 2017. “Experiments in Engagement: Designing Public Engagement with Science and Technology for Capacity Building.” Public Understanding of Science 26 (6): 634–649. doi:https://doi.org/10.1177/0963662515620970.
- Shakespeare, T. 2015. “Gene Editing: Heed Disability Views.” Nature 527: 446.
- Sharma, A., and C. T. Scott. 2015. “The Ethics of Publishing Human Germline Research.” Nature Biotechnology 33 (6): 590–592. doi:https://doi.org/10.1038/nbt.3252.
- Sherkow, J. S. 2019. “Controlling CRISPR Through Law: Legal Regimes as Precautionary Principles.” The CRISPR Journal 2 (5): 299–303. doi:https://doi.org/10.1089/crispr.2019.0029.
- Smolenski, J. 2015. “CRISPR/Cas9 and Germline Modification: New Difficulties in Obtaining Informed Consent.” The American Journal of Bioethics 15 (12): 35–37. doi:https://doi.org/10.1080/15265161.2015.1103816.
- Spivak, R. A., I. G. Cohen, and E. Y. Adashi. 2017. “Germ-line Gene Editing and Congressional Reaction in Context: Learning from Almost 50 Years of Congressional Reactions to Biomedical Breakthroughs.” Journal of Law & Health 30(1): 20–54.
- STAT. 2016. “STAT’s Stats of the Year: 2016 by the Numbers.” STAT (online). https://www.statnews.com/2016/12/28/stat-stats-year-in-numbers/.
- Stilgoe, J., S. J. Lock, and J. Wilsdon. 2014. “Why Should We Promote Public Engagement with Science?” Public Understanding of Science 23 (1): 4–15. doi:https://doi.org/10.1177/0963662513518154.
- Stilgoe, J., R. Owen, and P. Macnaghten. 2013. “Developing a Framework for Responsible Innovation.” Research Policy 42 (9): 1568–1580. doi:https://doi.org/10.1016/j.respol.2013.05.008.
- Stirling, A. 2008. ““Opening up” and “Closing Down”: Power, Participation, and Pluralism in the Social Appraisal of Technology.” Science, Technology, & Human Values 33 (2): 262–294. doi:https://doi.org/10.1177/0162243907311265.
- Stokes, D. E. 1997. Pasteur’s Quadrant: Basic Science and Technological Innovation. Washington, DC: Brookings Institution Press.
- Tomblin, D., Z. Pirtle, M. Farooque, D. Sittenfeld, E. Mahoney, R. Worthington, G. Gano, et al. 2017. “Integrating Public Deliberation into Engineering Systems: Participatory Technology Assessment of NASA’s Asteroid Redirect Mission.” Astropolitics 15 (2): 141–166. doi:https://doi.org/10.1080/14777622.2017.1340823.
- Toulmin, S. 1961. “Forecasting and Understanding.” Chap 1 in Foresight and Understanding, 18–43. New York, NY: Harper Torchbooks.
- Toulmin, S. 1966. “The Complexity of Scientific Choice II: Culture, Overheads, or Tertiary Industry?” Minerva 4 (2): 155–169.
- Urnov, F. D., J. C. Miller, Y. Lee, C. M. Beausejour, J. M. Rock, S. Augustus, A. C. Jamieson, M. H. Porteus, P. D. Gregory, and M. C. Holmes. 2005. “Highly Efficient Endogenous Human Gene Correction Using Designed Zinc-Finger Nucleases.” Nature 435: 646–651. doi:https://doi.org/10.1038/nature03556.
- van Mil, A., H. Hopkins, and S. Kinsella. 2017. Potential Uses for Genetic Technologies: Dialogue and Engagement Research Conducted on Behalf of the Royal Society. Hopkins Van Mil. https://royalsociety.org/topics-policy/publications/2018/genetic-technologies-public-dialogue/.
- Vidyasagar, D. 2006. “Global Notes: The 10/90 Gap Disparities in Global Health Research.” Journal of Perianatology 26: 55–56.
- Viotti, M., A. R. Victor, D. K. Griffin, J. S. Groob, A. J. Brake, C. G. Zouves, and F. L. Barnes. 2019. “Estimating Demand for Germline Genome Editing: An in vitro Fertilization Clinic Perspective.” The CRISPR Journal 2 (5): 304–315. doi:https://doi.org/10.1089/crispr.2019.0044.
- von Schomberg, R. 2013. “A Vision of Responsible Research and Innovation.” In Responsible Innovation: Managing the Responsible Emergence of Science and Innovation in Society, edited by R. Owen, J. Bessant, and M. Heintz, 51–74. West Sussex, UK: John Wiley & Sons. doi:https://doi.org/10.1002/9781118551424.ch3.
- Wade, N. 1999. “Patient Dies during a Trial of Therapy Using Genes.” The New York Times, September 29 (online). Retrieved from https://www.nytimes.com/1999/09/29/us/patient-dies-during-a-trial-of-therapy-using-genes.html.
- Weinberg, A. M. 1972. “Science and Trans-Science.” Minerva 10 (2): 209–222. doi:https://doi.org/10.1007/BF01682418.
- Weisberg, S. M., D. Badgio, and A. Chatterjee. 2017. “A CRISPR New World: Attitudes in the Public Toward Innovations in Human Genetic Modification.” Frontiers in Public Health 5 (117), doi:https://doi.org/10.3389/fpubh.2017.00117.
- Whitman, D., J. Love, G. Rainville, and L. Skufca. 2018. U.S. Public Opinion & Interest on Human Enhancements Technology. Washington, DC: AARP Research. doi:https://doi.org/10.26419/res.00192.001.
- Wiek, A., L. Gasser, and M. Siegrist. 2009. “Systemic Scenarios of Nanotechnology: Sustainable Governance of Emerging Technologies.” Futures 41 (5): 284–300. doi:https://doi.org/10.1016/j.futures.2008.11.016.
- Wilsdon, J., and R. Willis. 2004. See-through Science: Why Public Engagement Needs to Move Upstream. London: Demos. doi:https://doi.org/10.13140/RG.2.1.3844.3681.
- Wired. August 2015. Cover. Retrieved from https://www.wired.com/wp-content/uploads/2015/07/designer_genes_cover.jpg.
- Wired. April 2019. Cover. Retrieved from https://media.wired.com/photos/5c8985f8ee28c70e73e44087/master/w_1258,h_1655,c_limit/2704_crispr_cover_carve.jpg.
- Withycombe Keeler, L. 2014. “Quenching Our Thirst for Future Knowledge: Participatory Scenario Construction and Sustainable Water Governance in a Desert City.” Doctoral diss., Arizona State University.
- Withycombe Keeler, L., M. J. Bernstein, and A. D. Hudson. 2020. The Future of Ageing in Smart Environments: Scenarios of 2050 [workshop report]. Tempe, AZ: Arizona State University School for the Future of Innovation in Society, Global Futures Laboratory, and The Global KAITEKI Center.
- Withycombe Keeler, L., M. J. Bernstein, and C. Selin. 2019. “Intervening Through Futures for Sustainability Presents: Scenarios, Sustainability, and Responsible Research and Innovation.” In Socio-Technical Futures Shaping the Present, edited by A. Lösch, A. Grunwald, M. Meister, and I. Schulz-Schaeffer, 255–282. Wiesbaden, DE: Springer VS. doi:https://doi.org/10.1007/978-3-658-27155-8_12.
- Wolpe, P. R., K. S. Rommelfanger, and the Drafting and Reviewing Delegates of the BEINGS Working Groups. 2017. “Ethical Principles for the Use of Human Cellular Biotechnologies.” Nature Biotechnology 35 (11): 1050–1058. doi: https://doi.org/10.1038/nbt.4007.
- WHO. 2020. Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing—Call for Contributions. https://www.who.int/ethics/topics/human-genome-editing/consultation-2020/en/.
- Wynne, B. 2001. “Creating Public Alienation: Expert Cultures of Risk and Ethics on GMOs.” Science as Culture 10 (4): 445–481. doi:https://doi.org/10.1080/09505430120093586.
- Wynne, B. 2006. “Public Engagement as a Means of Restoring Public Trust in Science—Hitting the Notes, but Missing the Music?” Public Health Genomics 9 (3): 211–220. doi:https://doi.org/10.1159/000092659.